Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd. was founded in April 2009 by Dr. Yuxin Chen who studied in Canada and U.S., is a high technology biological and pharmaceutical corporation mainly engaged in research, development and production of antimicrobial peptide drugs and chemical drugs, and has a wholly owned R & D subsidiary, Changchun ProteLight Pharmaceutical & Biotechnology Co., Ltd.
In 2009, the corporation was awarded as one of the first group “Key Overseas Chinese Enterprise Team” by Overseas Chinese Affairs Office of The State Council. In 2014, the corporation was ranked as “The Most Promising seed-corporation in China” by EY which is the largest accounting firm in the world. In 2015, ProteLight’s independent R & D new drug project was jointly recommended as one of the seventeen “priority accelerated approval new drugs” by Ministry of Science and Technology and National Health Commission of the People’s Republic of China. In 2017, ProteLight’s two 1.1 category national innovative drugs were selected as national “13th five-year plan” major new drug innovative manufacture projects.
The corporation has received or applied for more than ten PCT Invention Patent, Chinese Invention Patent, US Invention Patent and EU Invention Patent, such as “One Antimicrobial Peptides and Methods of Preparation and Use”, “Antimicrobial Peptide and Methods of Use”, and “Antipruritic Composition and Use in Antipruritic Preparation”. The corporation has undertaken more than thirteen technology projects, including “12th five-year plan” and “13th five-year plan” key innovative new drug manufacture projects. All of ProteLight’s R & D projects are international initiative and have been strongly supported by the national and local governments. The category 1.1 anti-infective new drug, antimicrobial peptide PL-5 accessed to new drugs clinical official written reply in 2016, and it is in clinical trials now. Disinfection products in 26 bar code are sold nationwide in China.
The R & D team is led by Dr. Hartmut Michel, the Nobel Prize winner and Dr. Robert S. Hodges, Fellow of the Royal Society of Canada. Furthermore, ProteLight has established the “Hartmut Michel Institute of (Jiangyin) Biomedical Research” and “Robert (Jiantyin) Foreign Academician Station” to research and develop antifungal new drug PL-18, antimicrobial peptide eye drops PL-33, antitumor antimicrobial peptide small molecule drug PL-AC, etc.
In the future, based on the serial products of antimicrobial peptide, the corporation will continue to lay equal stress on R & D and production management, to explore the market with high quality innovative products, to strive to become a leader among international antimicrobial peptide pharmaceutical corporations.